Trypan Blue Versus Brillant Blue for Epiretinal Membranes

This study is currently recruiting participants.

Verified by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery, September 2008

First Received: September 21, 2008 Last Updated: September 22, 2008 History of Changes

Sponsored by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Information provided by:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
ClinicalTrials.gov Identifier:	NCT00757380

Purpose

Membraneppeling alone versus Membranepeeling with Membrane Limitans Interna Pelling using two different Dyes for Epiretinal Membrane Surgery.

Condition	Intervention
Idiopathic Epiretinal Membranes	Procedure: Trypan Blue Procedure: Brillant Blue

MedlinePlus related topics: Surgery

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment
Official Title:	Membranepeeling With Trypan Blue Versus Membranpeeling With Brillant Blue for Patients With Idiopathic Epiretinal Membranes

Further study details as provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

Primary Outcome Measures:

Secondary Outcome Measures:

Microperimetry optical coherence tomographie questionnaire (metamorphopsien) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	60
Study Start Date:	July 2008
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Group 1: Active Comparator Trypan Blue	Procedure: Trypan Blue Membranepeeling with TB
Group 2: Active Comparator Brillant Blue	Procedure: Brillant Blue Membranepeeling and membrana limitans interna peeling with BB

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00757380

Contacts

Contact: Susanne Binder, Univ. Prof. Dr.	+431711654607	susanne.binder@wienkav.at
Contact: Christiane I Falkner-Radler, Dr.	+431711654607	christiane.falkner-radler@wienkav.at

Locations

Austria
The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Recruiting
Vienna, Austria, 1030
Contact: Christiane I Falkner-Radler, Dr. +431711654607 christiane.falkner-radler@wienkav.at
Principal Investigator: Christiane I Falkner-Radler, Dr.

Sponsors and Collaborators

The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

Investigators

Study Chair:	Katharina Kreppler, Univ. Doz. Dr.	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Principal Investigator:	Christiane I Falkner-Radler, Dr.	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery

More Information

No publications provided

Responsible Party:	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery ( The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery )
Study ID Numbers:	FR-4-CI-2008
Study First Received:	September 21, 2008
Last Updated:	September 22, 2008
ClinicalTrials.gov Identifier:	NCT00757380 History of Changes
Health Authority:	Austria: Ethikkommission

Keywords provided by The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery:

epiretinal membranes
vitreoretinal dyes
membranepeeling

Study placed in the following topic categories:

Eye Diseases
Epiretinal Membrane
Diminazene aceturate
Retinal Diseases

Additional relevant MeSH terms:

Anti-Infective Agents
Trypanocidal Agents
Antiparasitic Agents
Antiprotozoal Agents
Therapeutic Uses

Eye Diseases
Epiretinal Membrane
Diminazene aceturate
Pharmacologic Actions
Retinal Diseases

ClinicalTrials.gov processed this record on May 07, 2009